• The gene therapy company Lysogene has raised $25 million from an IPO on Euronext Paris designed to fund its R&D work. “This IPO will enable us to pursue the development of two drugs to treat two polysdisabling, devastating and deadly diseases of the central nervous system, which start in infancy and lead to the patients premature death,” said CEO Karen Aiach. “By focusing directly on the cause, our treatments aim to cure these diseases the medical needs of which are largely unsatisfied and currently uncovered.
• The Chan Zuckerberg Biohub launched by FaceBook mogul Mark Zuckerberg and his wife has begun to dole out $50 million to 47 investigators who won 5 years of financial support for their research projects. The Biohub brings together Bay Area universities to collaborate on new research initiatives.
• The FTC has sued Shire ViroPharma for the tactics it used in fighting off a generic competitor to its antibiotic Vancocin HCI.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription